“Those who have knowledge, don’t predict. Those who predict, don’t have knowledge.” – Lao Tzu, 6th Century BC Chinese Poet
In 2016 I made mention publicly of only two equities that I really liked, Medivation and Portage Biotech.
Medivation I started to Tweet about in early April 2016 (see screenshot below) as a good candidate to be taken over by the end of the year. The stock at the time was trading around $40US. I had an aggressive target of $80. Just 100 days later, Pfizer said it had agreed to buy Medivation Inc. for $81.50 a share, valuing the total company at about $14 billion.
Portage Biotech is a penny stock that trades on the OTCBB at around .13c. ($PTGEF)
Many of the same players that built Medivation from a penny stock microcap to a $14 billion market cap takeover in 12 years are involved in Portage Biotech. A few weeks ago, Portage subsidiary company Biohaven completed a financing for $80 Million.
With Medivation now merged, Portage continues to be a favorite heading into 2017.
I look forward to finding you some more gems as soon as we uncover them.
Happy investing,
Anna Morera Leralta
As I thought and posted 8 days ago, Medivation, $MDVN received a takeover offer. The offer will be rejected – See my previous post.
— Anna Morera Leralta (@MedTechpreneur) April 28, 2016
We will never spam you or give your email address to a third party.